ACTRN12622000272796
撤回
4 期
Evaluation of the safety, tolerability and effectiveness of weekly tafenoquine for malaria prophylaxis in Vietnam People’s Army personnel in South Sudan
Australian Defence Force Malaria and Infectious Disease Institute0 个研究点目标入组 63 人2022年2月14日
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Malaria
- 发起方
- Australian Defence Force Malaria and Infectious Disease Institute
- 入组人数
- 63
- 状态
- 撤回
- 最后更新
- 3年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\)Adults (male and female).
- •2\)Glucose\-6\-phospate dehydrogenase (G6PD) normal enzyme activity levels (\>70%) of the site median value for G6PD normals using a quantitative G6PD test.
- •3\)Willing and able to comply with all monitoring visits, physical examination, adverse events questionnaire, laboratory tests, and other study procedures.
- •4\)Willingness to complete an acceptability questionnaire.
- •5\)Completion of the written informed consent process prior to undertaking any study\-related procedure.
排除标准
- •1\)G6PD deficiency.
- •2\)Prior or current history of nervous system and psychiatric disorders.
- •3\)Any participant who is directly involved in conducting the study.
- •4\)Any participant with poor peripheral venous access for blood sampling.
- •5\)Known hypersensitivity reactions to primaquine.
- •6\) Pregnant women.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
已完成
1 期
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10
招募中
2 期
Evaluation of the tolerability of sustained-release morphine for patients with interstitial lung diseaseJPRN-jRCTs041230028Suda Takafumi34
已完成
1 期
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment PeriodACTRN12622000680763Hope Medicine (Nanjing) Co., Ltd16
尚未招募
3 期
Study of Tuberculosis resistant to treatmentHealth Condition 1: J988- Other specified respiratory disordersCTRI/2021/03/032189International Union Against Tuberculosis and Lung Disease